Comparative Safety and Efficacy of Low-dose Vitamin D in Kidney Failure
小剂量维生素 D 治疗肾衰竭的安全性和疗效比较
基本信息
- 批准号:10721791
- 负责人:
- 金额:$ 18.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-01 至 2028-04-30
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAdherenceAgonistAlkaline PhosphataseAnimalsBenefits and RisksBlood VesselsBone DiseasesCalcitriolCalciumCardiovascular DiseasesCardiovascular systemCaringChronic Kidney FailureClinicalClinical TrialsComplementComplexDatabasesDepositionDevelopment PlansDialysis procedureDiscipline of NursingDiseaseDoseElectronic Health RecordEnrollmentEpidemiologyEventFoundationsFutureGoalsHarm ReductionHealth BenefitHemodialysisHydroxyapatitesHypercalcemiaHyperparathyroidismIn VitroInterruptionInterventionIntervention TrialIntravenousKidneyKidney FailureLeft Ventricular HypertrophyMaintenanceMeasuresMentorsMetabolicMetabolismMineralsNormal RangeOralOsteogenesisOutcomePTH geneParticipantPathologicPatientsPharmaceutical PreparationsPhysiciansPositioning AttributeProcessProviderResearchResearch DesignResearch PersonnelRetrospective cohort studyRiskSafetyScientistSerumSmooth Muscle MyocytesStructureTestingTitrationsTrainingTreatment CostVascular Smooth MuscleVascular calcificationVitamin DVitamin D3 Receptoracceptability and feasibilityarterial stiffnessbiomarker panelbonebone turnovercalcificationcardiovascular disorder riskcardiovascular risk factorcareer developmentcinacalcetclinical epidemiologyclinical practicecomparative efficacycomparative safetycoronary perfusioncostdesignepidemiologic dataexperiencefibroblast growth factor 23hospitalization ratesimprovedinorganic phosphateintravenous administrationmeetingsmortality riskmultidisciplinaryosteogenicpatient orientedpractice settingpragmatic trialpreventprimary outcomepromoterpublic health researchrandomized, clinical trialssafety testingskillssymposiumsynergismtranslational health sciencetreatment as usualtreatment strategytrial design
项目摘要
PROJECT SUMMARY/ABSTRACT
The components of chronic kidney disease-mineral and bone disorder (CKD-MBD) include calcitriol deficiency,
hyperphosphatemia, and excesses of fibroblast growth factor-23 (FGF-23) and parathyroid hormone (PTH), all
of which consistently and strongly associate with cardiovascular disease (CVD) in patients with kidney failure
on dialysis. Vascular calcifications are present in >80% of these patients and may be a mechanism through
which CKD-MBD increases CVD risk. Intravenously-administered (IV) vitamin D receptor agonists (VDRA) are
routinely used as first-line therapy for CKD-MBD in kidney failure, supported by experimental and
epidemiological evidence that suggest VDRAs improve CVD and survival. However, the long-term risks and
benefits of the current treatment approach, which encourages escalating VDRA doses to reduce PTH
concentrations towards the normal range, have never been tested by clinical outcomes trials. This approach
often leads to high VDRA doses which incur several risks: (1) a dose-dependent rise in FGF-23, a major risk
factor for CVD that is associated with monotonically increasing risk of death in kidney failure; (2)
hypercalcemia, a key promoter of vascular calcification; (3) low turnover bone disease, which drive calcium
and phosphate into the vasculature because they cannot deposit into bone; (4) held doses of VDRA as a result
of (2) and (3), which interrupts therapy and deprives patients of its likely health benefits.
The goal of this project is to evaluate the safety, efficacy, and feasibility of a low fixed-dose vitamin D strategy
to treat CKD-MBD in kidney failure to move the field towards identifying an optimal strategy that balances the
risks and benefits of VDRA use. The two Aims proposed will leverage a unique partnership with Northwest
Kidney Centers (NKC), the largest provider of dialysis in Seattle, WA. Aim 1 is a 12-month pragmatic
randomized clinical trial of 90 NKC patients on hemodialysis that will compare the effects of a low fixed-dose
oral calcitriol strategy (intervention) with the current usual care of PTH-titrated IV VDRAs (control) on a
comprehensive panel of biomarkers assessing mineral metabolism, bone turnover, and serum calcification
propensity, as well as measures of feasibility and acceptability. Aim 2 is a complementary retrospective cohort
study using the NKC electronic health records database that will test associations between mean VDRA dose
and variability in VDRA doses with CVD event and hospitalization rates. These Aims test whether a low fixed-
dose vitamin D strategy has causal effects that improve intermediate outcomes (Aim 1) and associate with
improved clinical outcomes (Aim 2), building a foundation for future large-scale clinical outcomes trials.
Integrated with this research agenda is a career development plan designed to position me to become a
successful independent investigator in the field of disordered mineral metabolism in CKD. This mentored
approach to training includes regular meetings with co-mentors who are established leaders in multi-
disciplinary fields, structured didactics, attendance at local and national conferences, and experiential training.
项目总结/摘要
慢性肾脏疾病-矿物质和骨疾病(CKD-MBD)的组分包括骨化三醇缺乏,
高磷酸盐血症,以及成纤维细胞生长因子-23(FGF-23)和甲状旁腺激素(PTH)过量,所有
其中持续且强烈地与肾衰竭患者的心血管疾病(CVD)相关
做透析血管钙化存在于>80%的这些患者中,并且可能是通过
CKD-MBD会增加CVD风险。静脉内施用(IV)维生素D受体激动剂(VEGF-C)是
常规用作肾衰竭中CKD-MBD的一线治疗,
流行病学证据表明VDRA可改善CVD和生存率。然而,长期风险和
目前治疗方法的益处,鼓励增加VEGFR 2剂量以降低PTH
浓度接近正常范围,从未通过临床结果试验进行过测试。这种方法
通常会导致高剂量的VEGFR 2,这会带来几种风险:(1)FGF-23的剂量依赖性升高,
与肾衰竭死亡风险单调增加相关的CVD因素;(2)
高钙血症,血管钙化的关键促进因素;(3)低转换骨疾病,其驱动钙
和磷酸盐进入脉管系统,因为它们不能存款到骨中;(4)因此,
(2)和(3),这中断了治疗,剥夺了患者可能的健康益处。
该项目的目标是评估低固定剂量维生素D策略的安全性、有效性和可行性
治疗肾衰竭中的CKD-MBD,以确定平衡
使用维生素C的风险和益处。提出的两个目标将利用与西北的独特伙伴关系
肾脏中心(NKC),华盛顿州西雅图最大的透析提供商。目标1是一个为期12个月的务实
一项在90名接受血液透析的NKC患者中进行的随机临床试验,将比较低固定剂量
口服骨化三醇策略(干预)与当前常规治疗PTH滴定IV VDRA(对照),
评估矿物质代谢、骨转换和血清钙化的综合生物标志物组
倾向,以及可行性和可接受性的措施。Aim 2是一个补充性回顾性队列
使用NKC电子健康记录数据库进行的研究,该数据库将测试平均维生素D剂量与
以及随CVD事件和住院率变化的VEGFR 2剂量。这些目标测试是否低固定-
剂量维生素D策略具有改善中间结果(目标1)的因果效应,并与
改善临床结局(目标2),为未来大规模临床结局试验奠定基础。
与此研究议程相结合的是一个职业发展计划,旨在使我成为一个
CKD矿物质代谢紊乱领域的成功独立研究者。这一指导
培训方法包括定期与共同导师会面,他们是多领域的领导者,
学科领域,结构化教学法,参加地方和国家会议,以及经验培训。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Simon Hsu其他文献
Simon Hsu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Simon Hsu', 18)}}的其他基金
F32 Childcare Costs Supplement: Assessment of the Vitamin D Metabolite Ratio as a Therapeutic Target in Clinical Practice
F32 儿童保育费用补充:维生素 D 代谢物比率作为临床实践中治疗目标的评估
- 批准号:
10517816 - 财政年份:2021
- 资助金额:
$ 18.77万 - 项目类别:
相似海外基金
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 18.77万 - 项目类别:
Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 18.77万 - 项目类别:
Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 18.77万 - 项目类别:
Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 18.77万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 18.77万 - 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 18.77万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 18.77万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 18.77万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 18.77万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 18.77万 - 项目类别:
Fellowship Programs